Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol + aspirin versus clopidogrel + aspirin in CYP2C19 loss-of-function acute minor ischemic stroke
ChiCTR2400091121Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cilostazol, clopidogrel and aspirin in ischemic stroke (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Proportion of new stroke events within 3 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
cilostazolclopidogrelaspirin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400091121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091121.